Skip to main
DERM

DERM Stock Forecast & Price Target

DERM Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Journey Medical Corp has demonstrated significant growth in both payer access and prescriber adoption, with coverage of commercial lives increasing from approximately 30% in May to around 65% by July, impacting over 100 million lives. The number of prescribers utilizing Journey's products also reflects this momentum, escalating from about 660 in the first quarter to over 1,800 by the second quarter, indicating robust market traction. Furthermore, Journey’s established brand value, particularly for its product Accutane, enhances consumer loyalty and helps maintain its competitive market share in the dermatological sector.

Bears say

Journey Medical Corp faces a negative outlook primarily due to a significant decline in prescriptions for its flagship product, Accutane, dropping from 93,000 in Q1 2024 to approximately 66,000 in Q1 2025. The company also faces key challenges, including competitive pressures from both branded and generic rosacea treatments, uncertainty surrounding the uptake and reimbursement of its product Emrosi, and ongoing regulatory risks associated with its portfolio programs. Additionally, financial sustainability is threatened by potential cash burn exceeding current projections and the effectiveness of its sales force scaling efforts.

DERM has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Journey Medical Corp (DERM) Forecast

Analysts have given DERM a Strong Buy based on their latest research and market trends.

According to 3 analysts, DERM has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Journey Medical Corp (DERM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.